Defendant
1 case as defendant.
Glenmark Pharmaceuticals Inc., USA is the North American subsidiary of Glenmark Pharmaceuticals Ltd., a global pharmaceutical company headquartered in Mumbai, India. The parent company was founded in 1977 and is publicly traded on the Bombay Stock Exchange (BSE: 532296) and the National Stock Exchange of India (NSE: GLENMARK). The U.S. subsidiary was established in 2003. The global parent company, Glenmark Pharmaceuticals Ltd., generated revenues of approximately $1.6 billion to $1.86 billion in recent fiscal years and employs over 15,800 people worldwide. Glenmark Pharmaceuticals Inc., USA is headquartered in Mahwah, New Jersey, and also has a U.S. manufacturing facility in Monroe, North Carolina.
Glenmark Pharmaceuticals Inc., USA operates as a pharmaceutical company with both generic and branded products for the U.S. market. The company's generic portfolio is extensive, with over 130 drugs authorized for distribution in the United States. These products cover a wide range of therapeutic areas, including dermatology, hormones, controlled substances, oncology, and oral contraceptives. The company also develops and commercializes branded specialty products through its subsidiary, Glenmark Therapeutics Inc., focusing on dermatology and respiratory treatments. Notable products include Ryaltris, a nasal spray for seasonal allergic rhinitis. The company's innovation efforts are concentrated in the therapeutic areas of respiratory, dermatology, and oncology.
Based on the provided data, Glenmark Pharmaceuticals Inc., USA is an operating company that acts as a defendant in patent litigation. The company has been named as a defendant in one tracked case and has not appeared as a plaintiff. This defensive posture is typical for pharmaceutical companies that manufacture and sell generic drugs, which often face patent challenges from brand-name drug manufacturers. The single tracked case, Veloxis Pharmaceuticals, Inc. v. Glenmark Pharmaceuticals Inc., USA, was filed in the U.S. District Court for the District of Delaware, a common venue for patent litigation.
This is an Abbreviated New Drug Application (ANDA) case filed by Veloxis Pharmaceuticals against Glenmark Pharmaceuticals in the District of Delaware. Filed in March 2026, the case is currently open.